T-Cell Non-Hodgkin's Lymphoma


The First CAR-T Therapy Heading to the FDA (September 29, 2016)

Kite Pharma reported that its CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with aggressive non Hodgkin lymphoma. The interim results from the phase... Continue Reading

Opdivo® Highly Effective for Some Patients with Lymphomas (August 16, 2016)

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell lymphomas. These... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer... Continue Reading

CART Therapy Promising in Lymphomas (February 9, 2016)

The use of a patient’s own immune cells to fight cancer through a technique called CART therapy, is proving to be a promising therapeutic approach in the treatment of some lymphomas. These results were... Continue Reading

Deadly and distinctive: Cancer caused by gene deletions (July 28, 2015)

By Bill Hathaway A deadly form of T cell lymphoma is caused by an unusually large number gene deletions, making it distinct among cancers, a new Yale School of Medicine study shows. Researchers conducted... Continue Reading

What’s New in the Management of Lymphoma? (March 2, 2015)

What’s New in the Management of Lymphoma? Cancers that begin in cells of the lymph system are referred to as malignant lymphomas. Lymphomas range from aggressive to slow growing or indolent and can be... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (December 17, 2014)

CancerConnect News: HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood... Continue Reading

FDA Approves Beleodaq for Peripheral T-cell Lymphoma (July 24, 2014)

The FDA announces its approval of Beleodaq (belinostat), a histone deacetylase inhibitor for treating peripheral T-cell lymphoma (PTCL), based on the results of the BELIEF study that found an overall response... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published... Continue Reading

Targeted Agent Xalkori May Benefit Children with Anaplastic Lymphoma (May 23, 2012)

The targeted agent Xalkori® (crizotinib) appears to drastically reduce the size of tumors in children with refractory anaplastic large cell lymphoma, according to the results of a phase I study that will... Continue Reading

Lymphoma During Pregnancy Can Have Good Outcomes (March 14, 2012)

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients.... Continue Reading

Additional Rare Cancer Cases Reported Among Users of TNF Blockers (April 19, 2011)

The US Food and Drug Administration (FDA) has received additional reports of a rare type of cancer—hepatosplenic T-cell lymphoma—primarily among adolescents and young adults who are being treated for... Continue Reading

Folotyn Benefits Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (February 3, 2011)

In the Phase II PROPEL study, 29% of patients with relapsed or refractory peripheral T-cell lymphoma (a type of non-Hodgkin’s lymphoma) experienced a complete or partial disappearance of detectable cancer... Continue Reading

Istodax Active against Refractory Cutaneous T-cell Lymphoma (August 31, 2010)

Final results from a Phase II clinical trial provide additional evidence that Istodax® (romidepsin) is active against refractory cutaneous T-cell lymphoma. These results were published in the Journal... Continue Reading

Survivors of Some Childhood Cancers May Face Cognitive Impairment (May 18, 2010)

Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according... Continue Reading

Ontak Delays Progression of Patients with Cutaneous T-cell Lymphoma (March 29, 2010)

Among patients with cutaneous T-cell lymphoma, treatment with the drug Ontak® (denileukin diftitox) slows disease progression. These results were reported in the Journal of Clinical Oncology. T-cell lymphoma,... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS